A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Summary

The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Zimberelimab (ZIM)

  Administered intravenously

• Drug
  Domvanalimab (DOM)

  Administered intravenously

• Drug
  Sacituzumab govitecan-hziy (SG)

  Administered intravenously

• Drug
  Etrumadenant (ETRUMA)

  Administered orally

• Drug
  Carboplatin

  Administered intravenously

• Drug
  Cisplatin

  Administered intravenously

• Drug
  Pemetrexed

  Administered intravenously

Locations (100)